tumour invasion assays

Additional Info

  • Overview:

    Melanoma Grant

    Title

    Molecular Dissection of Melanoma Progression

    Co-ordinator          Prof. William Gallagher, University College Dublin (UCD)
    Partners Cellix Ltd, Conway Institute, University College Dublin (Co-ordinator), Institut d'Investigacio Biomedica de Bellvitge, University of Maastricht, University Hospitals, Katholieke Universiteit Leuven, Swedish Human Proteome Resource, Uppsala University, OncoMethylome Sciences, SlidePath, OncoMark Ltd
    Funding Body EU Commission
    Grant Type Marie Curie Fellowship Industry Academia Partnership (FP7)*
    Date 1 August 2009 – 1 August 2014
    Total Grant Amount €1,736,483
    Results Project is ongoing
    Keywords Melanoma, Metastasis, Microarrays, 1205lu Cells, in-vitroin-vivo imaging
    Contact This email address is being protected from spambots. You need JavaScript enabled to view it. or phone +353-1-4500-1550
    Project Website Target Melanoma
    Cellix's contribution to Target-Melanoma:
    Cellix was involved in the development of functional cell-based screening assays to investigate cell-cell adhesion of melanoma cell lines.  Furthermore, we developed an invasion assay which models flow profiles in our new VenaT4 biochip. 
     
    Overall Project Aims:
    We are investigating the molecular basis underlying this difficult-to-treat disease, focusing on the discovery of new biomarkers (i.e. indicators) or potential targets for therapy.  Specifically, several of the academic groups in this consortium bring expertise in relation to the study of melanoma progression and epigenetic mechanisms. In addition, they will be providing access to tumour samples, which will be used throughout the project.
     
    More detail:
    Gene expression profiling experiments have begun to identify differences in transcriptomic patterns in melanoma progression. A key study by Winnepenninckx et al. (2006) represents one of the most extensive transcriptomic investigation of melanoma to date, where a 254-gene classifier for 4-year distant metastasis–free survival was determined. In further experimental work, several down regulated genes were shown to be DNA methylated- which causes a loss of expression of tumour suppressor genes, which may in turn contribute to the progression of cancer .  This project took advantage of this melanoma transcriptomic data, to identify novel biomarkers and functional mediators of the disease. Such information also opens the door for the identification of putative therapeutic targets. One of the main objectives of this proposal is also to identify DNA methylation of key regulators of melanoma, which will be a key aspect of collaborative exchange within the consortium. This project also involves significant interplay between industrial and clinical spheres. By further developing and sharing our combined set of skills, we will apply the latest developments in tissue microarray (TMA), DNA methylation and in vitro techniques to fast-track validation of putative melanoma targets identified from transcriptomic screens.
     
    The main goals of this Target-Melanoma:
    • Identification of methylated genes involved in melanoma progression (benign nevi to metastasis) and methylation profiling in clinical samples.
    • Validation and functional interrogation of melanoma progression-associated genes via tissue microarray (TMA) technologies and in vitro analysis.
    *The Marie Curie Fellowship Industry Academia Partnership funding is available for universities, research organisations, and businesses in the EU or Associated States to provide early-stage researchers of any nationality or age with structured scientific or technological training opportunities of between three months to three years.
  • Recommended Products:

    Biochips

    VenaT4 - chemotaxis, transmigration & invasion assays
    The VenaT4™ biochip for chemotaxis, transmigration and...

    Vena8 Endothelial+
    The Vena8 Endothelial+™ biochip is ideal for cell-cell...

    Microfluidic Pumps

    Kima - iPod Touch Microfluidic Pump
    The Kima™ pump is a microfluidic recirculating pump...

    Mirus Evo Nanopump - PC controlled
    The Mirus™ Evo Nanopump is a microfluidic syringe pump PC...

    ExiGo - iPad mini or LabVIEW controlled Microfluidic Pump
    The ExiGo™ pump is a microfluidic syringe pump controlled...